- Lancet Digital Health study highlights Lunit INSIGHT CXR as
top performer in TB screening, showing promise for improving
detection in high-burden settings
SEOUL,
South Korea, Aug. 6, 2024
/PRNewswire/ -- Lunit, a leading provider of AI-powered
solutions for cancer diagnostics and therapeutics, today announced
that its AI-powered chest X-ray analysis software, Lunit INSIGHT
CXR, has demonstrated superior performance in tuberculosis (TB)
detection in a large-scale, independent study published in The
Lancet Digital Health.
Despite being a curable disease, TB remains the world's second
leading cause of death from a single infectious agent, with an
estimated 10.6 million new cases in 2022. A major challenge in TB
control is underdiagnosis, with 3.1 million cases going
undetected that year. While chest X-rays are more sensitive than
symptom screening, their effectiveness is often limited by
variability in human interpretation and a shortage of radiologists
in high-burden countries. This context underscores the critical
importance of advanced AI assistance.
The study, conducted by Dr. Zhi Zhen
Qin and a team of researchers from the Stop TB Partnership
at UNOPS and Heidelberg University Hospital, evaluated 12
commercially available AI products for TB detection using data from
South Africa's national TB
prevalence survey. Lunit INSIGHT CXR achieved the highest area
under the receiver operating characteristic curve (AUC) of 0.902,
significantly outperforming other products.
Key findings for Lunit INSIGHT CXR include:
- Highest AUC (0.902) among all tested products
- 89.9% sensitivity at 67.7% specificity, meeting WHO target
product profile
- 89.5% sensitivity at 70.2% specificity, meeting WHO target
product profile
- Ability to maintain high sensitivity (>90%) across a wide
range of thresholds
The study, which included 774 participants (258
bacteriologically confirmed TB cases), is the first to
comprehensively evaluate multiple AI products in a high TB
setting.
"This landmark study not only showcases our AI's superior
accuracy but also demonstrates its alignment with WHO standards,"
said Brandon Suh, CEO of Lunit.
"Lunit INSIGHT CXR's ability to maintain high sensitivity across
diverse populations and thresholds is particularly crucial in
resource-limited settings, where every undetected case can have
far-reaching consequences. By bridging the gap in TB diagnosis, we
are contributing to a future where no case goes undetected,
especially in regions where it matters most."
The study's findings have significant implications for TB
screening in high-burden settings. Lunit INSIGHT CXR's robust
performance, particularly its ability to maintain high sensitivity
across various thresholds, allows for tailored screening
strategies. This adaptability enables healthcare systems to
optimize detection rates while managing available resources for
confirmatory testing, potentially leading to more accessible and
cost-effective TB programs in diverse healthcare settings.
About Lunit
Founded in 2013, Lunit is a medical AI company on a mission to
conquer cancer. We harness AI-powered medical image analytics and
AI biomarkers to ensure accurate diagnosis and optimal treatment
for each cancer patient. Our FDA-cleared Lunit INSIGHT suite for
cancer screening serves over 3,500 hospitals and medical
institutions across 50+ countries.
Our clinical findings are featured in top journals, including
the Journal of Clinical Oncology and the Lancet Digital Health, and
presented at global conferences such as the ASCO and RSNA.
In 2024, Lunit acquired Volpara Health Technologies, setting the
stage for unparalleled synergy and accuracy, particularly in breast
health and screening technologies.
Headquartered in Seoul, South
Korea, with a network of offices worldwide, Lunit leads the
global fight against cancer. Discover more at lunit.io.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lunits-ai-for-tuberculosis-detection-tops-in-12-product-comparative-study-302215413.html
SOURCE Lunit